BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $189 from $178 and keeps an Outperform rating on the shares. The firm ...

Bank of America upped their price target on shares of Quest Diagnostics from $179.00 to $182.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. UBS Group lifted ...

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

the average one-year price target for Quest Diagnostics is $182.07/share. The forecasts range from a low of $161.60 to a high of $199.50. The average price target represents an increase of 7.56% ...

During the last three months, 9 analysts shared their evaluations of Quest Diagnostics DGX, revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report) and Align Tech (ALGN – Research Report). Stay Ahead of the Mar ...